Loading... Please wait...

Categories

Our Newsletter


PF-2341066 (Crizotinib) | cMet/ALK inhibitor

  • PF-2341066 (Crizotinib).jpg
  • PF-2341066 (Crizotinib), 400x400px, png

Price:
$109.00
SKU:
C7234-5
Quantity:
Buy in bulk and save

Product Description

PF-2341066 (Crizotinib) is an orally-available, ATP-competitive, aminopyridine-based dual inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectively. [1] A kinase selectivity panel shows that PF-2341066 is selective against most tyrosine and serine-threonine kinases, with modest activity with Ron (IC50, 80 nM). [2] PF-2341066 inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, and invasion of human tumor cells in vitro at IC50s of 5 to 20 nM.

PF-2341066 has been shown to be effective in osteosarcoma growth [3] and anaplastic large-cell lymphomas [4].

Technical information:

Chemical Formula:   C21H22Cl2FN5O
CAS #:   877399-52-5
Molecular Weight:   450.34
Purity:   >99%
Appearance:   White
Chemical Name:   3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
Solubility:   Up to 40 mM in DMSO
Synonyms:   Crizotinib, PF-02341066, PF-2341066, PF 2341066, PF2341066

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.

Reference:

1. Zou et al., An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67, 4408-4417. Pubmed ID: 17483355
2. Cui et al., Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 2011, 54, 6342-6363. Pubmed ID: 21812414
3. Sampson et al., The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J. Bone. Miner. Res. 2011, 26(6), 1283-1294. Pubmed ID: 21308771
4. Christensen et al., Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6, 3314-3322. Pubmed ID: 21812414

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Add to Wish List

Click the button below to add the PF-2341066 (Crizotinib) | cMet/ALK inhibitor to your wish list.

You Recently Viewed...